Cardiovascular effects of Leptin;Lepti̇ni̇n kardi̇yovasküler etki̇leri̇

Erciyes Tip Dergisi

Volumn 27, Issue 4, 2005, Pages 167-176

  Dursun, Nurcan ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Cardiovascular diseases; Hypertension; Leptin; Obesity; Sympathetic nervous system

Indexed keywords

LEPTIN; LEPTIN RECEPTOR;

ADRENERGIC SYSTEM; BODY FAT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; HORMONE ACTION; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; INSULIN SENSITIVITY; METABOLIC REGULATION; NATRIURESIS; OBESITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THERMOGENESIS;

EID: 31444453162     PISSN: 1300199X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. J.Ren. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrin 2004; 181: 1-10.
2. Bartun M, Carmona R, Ortmann J, Kneger JE et al. Obesity- associated activation of angiotensin and endothelin in the cardiovascular system. IJ BCB, 2003; 3: 826-837.
3. Hall J E, Henegar JR, Dwyer TM, Liu J et al. Is obesity a major cause of chronic kidney disease. Adv Renal Replace Th, 2004; 11(1): 41-54.
4. Hall JE, Crook ED, Jones DW, Wofford MR and Dubbert PM. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci, 2002; 324: 127-137.
5. Zhang W, Telemague-Potts S, Andersan PR, Wang Z. et al. Adenoviral leptin as gene therapy for obesity related hypertension. Am J Hypertens 2002; 15: 1A (Abstract).
6. Friedmen JM. The function of leptin in nutrition, weight and physiology, Nutr Rev 2002; 60: 51-514.
7. Ahima RS, Osei SY. Leptin signaling. Phys Behav 2004; 81 223-241.
8. Tartaglia LA. The leptin receptor. J Biol Chem 1997; 272: 6093-6096.
9. Peelman F, Waelput W, Iserentat H et al. Leptin: linking adipocite metabolism with cardiovascular and autoimmune disease . Prog Lipid Res 2003; 43: 283-301.
10. Chua SC, Chung WK Wu-Peng Xset al. Phetypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 1996; 271: 1994-1996
11. Clement K, Vaisse C, Nahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392: 398-401.
12. Wu-Peng XS, Chua SC, Okada N, Liu SM, Nicolson M, Leibel RL. Phenotype of the obes Koletsky(f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor ( Lepr): evidence for deficient plasma-to-CSI transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 1997; 46: 513-518.
13. Banks WA. The many lives of leptin. Peptides 2004; 25: 331-338.
14. Bjorback C., Elmquist JK, Michl P et al. Expression of leptin receptor isoforms in rat brain microvessels. Endocrinology 1998; 139: 3485-3491.
15. Golden PL, Maccagnan TJ, Pardridge WM. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. J Clin Invest 1997; 99: 14-18.
16. Takaya K, Ogawa Y, Hiraoka J et al. Nonsense mutation ofleptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat Genet 1996; 14: 130-131.
17. Muraoka O, Xu B, Tsurumaki T et al. Leptin-induced transactivation of NPY gene promoter mediated by JAK 1, JAK2 and STAT 3 in the neural cell lines. Neurochem Int 2003; 42: 591-601.
18. Niswender KD, Schwartz MW. Insulin and revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrin 2003; 2: 1-10.
19. Stenvinkel P. Leptin and blood pressure-is there a link. Nephrol Dial Transplant 2000; 15: 115-117.
20. Clinical Guidelines on the Identification, Evaluation and Threatment of Overweight and Obesity in Adults; The Evidence Report Bethesda, MD. National Institutes of Health, NIH publication 1998, 98-4083.
21. Grundy SM. Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002; 105: 2696-2698.
22. Lakka HM, Tuomilehto J, Soleman JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J 2002; 23: 706-713.
23. Sowers JR. Obesity as a cardiovascular rise factor. AM J Med 2003; 115(8A): 37-41.
24. Hotta K, Funahashi T, Arita Y et al. Plasma concentrations of a novel, adipose -specific protein , adinopectin in type 2 diabetic patients. Arterioscler Thromb Vase Biol 2000; 20: 1595-1599.
25. Matsuzawara Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X;contribution adipocytokines adipocyte derived bioactive substances. Ann N Y Acad Sci 1999; 892: 146-154
26. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator- activated receptor- agonist, rosiglitazone, increases plasma levels of adinopectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
27. Yudkin JS, Stehawer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects; associations with obesity, insulin rezistance, and endothelial dysfunction. A potential for cytokines orginatingfrom adipose tissue?. Arterioscler Thomb Vasc Biol 1999; 19: 972-978.
28. Nisson J, Jovinge S, Niemann A et al. Relationship between plasma tumor necrosis factor- and insulin sensitivity in elderly men with non-insulin dependent diabetes mellitus. Arterioscler Thomb Vasc Biol. 1998; 1, 1199-1202.
29. Mertens I, Wander PM, Corthoust B et al. Visceral fat is a determinant of PAI-1 activity in diabetic and nondiabetic ovrweight and obese women. Horm Metab Res 2001; 33: 602-607.
30. Correia MLG and Haynes WG. Obesity- related hypertension: Is there a role for selective leptin resistance?. Curr Hypertens Reports 2004; 6: 230-235.
31. Bjorbaek C, Elmquist JK, Frantz JD et al. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell 1998; 1: 619-625.
32. Özata M, Özdemir IC, Licinio J: Human leptin deficiency caused by a missense mutation: Multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin- mediated defects. J. Clin Endocrinal Metab. 1999; 10: 3686-3695.
33. Dunbar JC, HuY, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activation by leptin. J Clin Invest 1997; 100: 270-278.
34. Shek EW, Brands MW and Hall JE. Chronic leptin infusion increased arterial pressure. Hypertension. 1998; 31: 409-414.
35. Correia ML, Morgan DA, Sivitz WI et al. Leptin acts in the central nervous system to produce dose-dependent changes in arterial pressure. Hypertension 2001; 37: 936-942.
36. Haynes WG, Morgan DA, Djalali A et al. Interactions between the melanocortin system and leptin in control of sympathetic nevre traffic. Hypertension 1999; 33: 542-547.
37. Correia ML, Morgan DA, Chapleau MA et al. Differantial modulation of leptin-inducedsympatoexcitation by baroreflex activation. J Hypertens 2002; 20: 1633-1641.
38. Correia ML, Hayne WG. Leptin, obesity, and cardiovascular disease. Curr Opin Nephrol Hypertens 2004; 13: 215-223.
39. Matsumura K, Tsuchihashi T, Fuji K, Lida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Peptides 2003; 11: 79-86.
40. Egawa M, Yoshimatsu H, Bray GA. Neuropeptide supresses action of neuropeptide Y in conscious rabbits. Hypertension 2000; 3: 1040-1044.
41. Dunbar JC, LU H. Proopiomelanocortin (POMC) products in the central regulation of sympathetic and cardiovascular dynamics; studies on melanocortin and opioid interactions. Peptides 2000; 21: 211-217.
42. Kuhar MJ, Adams LD, Hunter RG, Vechia SD, Smith Y. CART Peptides. Regul Pept 2000; 89: 1-6.
43. Beltowski J Wojcicka G, Gorny D, Marcinial A. Human leptin administered intraperitoneally stimulates natriurezis and decreases renal medullary Na+, K+ -ATP ase activity in the rat- impaired effect in dietary- induced obesity. Med Sci Monit 2002; 8(6): BR221-229.
44. Stenvinkel P, Lannquist F, Schalling M. Molecular studies of leptin : Implacations for renal disease. Nephrol Dial Transplant 1999; 14: 1103-1112.
45. Wolf G, Chen Sheldon, Han DC, Ziyadeh N. Leptin and Renal Disease. AJKD, 2002; 39 (1): 1-11.
46. Villerreal O, Reams G, Freeman RH, Taraben A. Renal effects of leptin in normotensive, hypertensive, and obese rats. Am J Physiol 1998; 275, R 2056-2060.
47. Praga M. Obesity- a neglected culprit in renal disease. Nephrol Dial Transplant. 2002; 17: 1157-1159.
48. Stenvinkal P. Leptin and blood pressure-is there a link? Nephral Dial Transplant. 2000; 1: 1115-1117.
49. Xiong Y, Tanaka H, Richardson JA, Williams SC et al. Endothelin-1 stimulates leptin production in adipocytes. J. Biol chem. 2001; 276 (30): 28471-28477.
50. Vecchione C, Maffei A, Collelta S, Aretini A et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phoshorylation pathway. Diabetes 2002; 51: 168-178.
51. Gündüz Z, Dursun N, Okur H, Koç N, Poyrazoĝlu MH. Siçanlarda uzun süreli leptin infüzyonunun renal hemodinami üzerine etkileri. 2003; Türk Fizyolojïk Bilimler Derneĝi 29. Ulusal Kongresi, ss 38
52. Narkiewicz K, Somers UK, Mos L, Kato M et al. An independent relationship between plasma leptin and heart rate in untreated patients with essential hypertension. J Hypertension. 1999; 17: 245-249.
53. Nickola MW, Wold LE, Colligan PB, Wang GJ et al. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension. 2000; 36: 501-505.